James Wisecarver

Kenneth Bloom has become chief medical officer of advanced pathology and genomic services at Invicro and Ambry Genetics, both part of Konica Minolta. Previously, he was president and head of oncology and immunotherapy at Human Longevity, and before that, chief medical officer of in vitro diagnostics, life sciences at General Electric. He also served as president and CEO of the medical group of Clarient Pathology Services, which was acquired by GE. Prior to that, he held various academic positions, including director of laboratory operations and chief information officer at the Rush Cancer Institute, clinical professor of pathology at the University of Southern California Keck School of Medicine, and associate professor of pathology at Rush Medical College. Bloom holds an MD from Rush Medical College and a BA from Grinnell College.

Vermillion has appointed Chris Goulart to the newly created position of senior vice president of commercial operations. He has held several sales, marketing, and business development positions, most recently at Natera where he was director of commercial development. He was also VP of sales and marketing for genetics laboratory joint venture between Fresenius Medical Chare and Shiel Holdings, and prior to that, Goulart was the director of international sales and managed care for Recombine, which was acquired by Cooper Surgical. 

Rohan Hastie was named president and CEO of Metabolon. He replaces John Ryals, who retired from those posts, but will remain on the company's board. Ryals has been president, CEO, and a board member of Metabolon since April 2002, when he cofounded the firm. 

Hastie joined Metabolon in September 2017 as chief business officer. Before that, he was president of consulting firm Arrow Life Sciences & Healthcare. He also has held leadership positions in diagnostics and corporate development at Hologic, where he was most recently president of Hologic Diagnostic Solutions.

Cancer Genetics has appointed Michael McCartney its chief commercial officer, effective immediately. McCartney was previously CEO of SciKon Innovation, an early-stage life science company. Before that, he was SciKon's COO. He has more than 20 years of experience in the life science space including stints at Roche, Siemens, and Abbott. 

Vortex Biosciences has appointed Bob Englert as its new CEO. Englert, who was previously the firm's chief technology officer, replaces exiting CEO Gene Walther, who has resigned to pursue other interests and will step down both from his position as CEO and as a member of the company's board.

Englert has over 25 years of experience in medical devices and life sciences, with a particular focus on IVD, point of care, and digital health solutions. Before joining Vortex, he served as CEO and founder of Biomedtrics, a diabetes data management company, and prior to that he was COO of Pelikan Technologies. Earlier in his career, Englert also held multiple senior roles at Abbott Laboratories. He holds a BS in biology from the University of Illinois Urbana-Champaign.

Vortex also said that Steve Crouse, who has been the company's chief commercial officer since March 2016, will now assume the position of chief operating officer. Prior to joining Vortex, Crouse served as senior vice president of sales and marketing at Freeslate, a company focused on providing laboratory automation to chemical and pharmaceutical companies.

Raymond Akers has resgined from the board of directors of Akers Biosciences, effective immediately. In a document filed with the US Securities and Exchange Commission dated June 1, the firm said that it believes Akers resigned due to "his significant differences with other members of the board regarding management of the company, its accounting and business practices, and its counsel." Last week, the company said that it had been granted a 180-day extension to meet a listing requirement of the Nasdaq calling for a minimum $1 per share closing bid price for 10 consecutive business days. The company added that the board's audit committee has been reviewing certain revenue recognition items for Q1 2018 and previous quarters. "The company believes Dr. Akers has not been fully cooperative in connection with such review," it said in its SEC document. 

Jersey, Channel Islands-based Quotient appointed Franz Walt as its CEO. He has 30 years of experience in leadership roles at Siemens Healthineers and Roche, Quotient said. He retired earlier this year as president of Siemens Healthineers, Laboratory Diagnostics, and was appointed interim CEO at Quotient in March.